Mirum Pharmaceuticals (NASDAQ:MIRM) focuses on developing and commercializing a range of therapies aimed at rare and life-threatening liver diseases. Through a combination of innovative research and drug development, the company is dedicated to significantly impacting the lives of patients who have limited treatment options. Their portfolio includes projects at various stages of development, targeting conditions such as Alagille syndrome, Progressive Familial Intrahepatic Cholestasis, and Biliary Atresia among others. Mirum Pharmaceuticals' main objective is to bring transformative treatments to market, improving patient outcomes and quality of life for those affected by these challenging diseases.